Huang Lab @ UCSF
@benhuanglab.bsky.social
@ UCSF acute myeloid leukemia: cancer modeling, molecular therapeutics, and functional genomics. We're hiring postdoctoral scholars!
@ huanglabucsf.com
@ huanglabucsf.com
Excited to share that our work was published in @JCO_ASCO! A report from the @COGorg: stem cell transplantation is associated with improved outcomes for children diagnosed with high-risk acute myeloid leukemia (AML).
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group
PURPOSEHematopoietic stem cell transplantation (HSCT) is used as consolidation for pediatric
patients with high-risk AML in first complete remission (CR1). The definition of high-risk
AML has evolved ...
ascopubs.org
April 29, 2025 at 1:54 PM
Excited to share that our work was published in @JCO_ASCO! A report from the @COGorg: stem cell transplantation is associated with improved outcomes for children diagnosed with high-risk acute myeloid leukemia (AML).
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Excited to share our preprint (manuscript in review): TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous cancer that is associated with poor outcomes. Revumenib and other menin inhibitors have shown promising activity against AMLs with KMT2A -rearrangements...
www.biorxiv.org
March 31, 2025 at 3:57 AM
Excited to share our preprint (manuscript in review): TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...